TY - JOUR
T1 - Tumorlokalisaties op PSMA-PET/CT bij patiënten met een persisterend meetbaar PSA na een radicale prostatectomie
AU - Ettema, Rosemarijn H.
AU - Meijer, Dennie
AU - Donswijk, Maarten L.
AU - Bodar, Yves J. L.
AU - van Leeuwen, Pim J.
AU - van der Poel, Henk G.
AU - Vogel, Wouter V.
AU - Nieuwenhuijzen, Jakko A.
AU - Hendrikse, N. Harry
AU - Oprea-Lager, Daniela E.
AU - Vis, André N.
N1 - Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - The aim of this study was to determine the role of PSMA-PET/CT imaging in patients who experience biochemical persistence (BCP) after robot-assisted laparoscopic radical prostatectomy (RARP). 150 patients with BCP after RARP who underwent radiolabeled PSMA-PET/CT imaging were evaluated. A multivariable logistic regression analysis was performed to identify predictors for the detection of metastases outside the prostatic fossa (≥ miN1) on PSMA-PET/CT. Results: In total, 89/150 patients (59%) had ≥ miN1 on PSMA-PET/CT at BCP. On multivariable analysis, higher PSA-values after RARP (p = 0.004) and positive pathological lymph node status (p = 0.006) were independent predictors for ≥ miN1. In presence of BCP, a high proportion of patients had ≥ miN1 disease, indicated by PSMA-PET/CT. Higher PSA-levels after RARP and positive pathological lymph node status were significantly associated with metastases outside the prostatic fossa. In conclusion, in patients with BCP, PSMA-PET/CT imaging is warranted to guide (salvage) treatment strategies.
AB - The aim of this study was to determine the role of PSMA-PET/CT imaging in patients who experience biochemical persistence (BCP) after robot-assisted laparoscopic radical prostatectomy (RARP). 150 patients with BCP after RARP who underwent radiolabeled PSMA-PET/CT imaging were evaluated. A multivariable logistic regression analysis was performed to identify predictors for the detection of metastases outside the prostatic fossa (≥ miN1) on PSMA-PET/CT. Results: In total, 89/150 patients (59%) had ≥ miN1 on PSMA-PET/CT at BCP. On multivariable analysis, higher PSA-values after RARP (p = 0.004) and positive pathological lymph node status (p = 0.006) were independent predictors for ≥ miN1. In presence of BCP, a high proportion of patients had ≥ miN1 disease, indicated by PSMA-PET/CT. Higher PSA-levels after RARP and positive pathological lymph node status were significantly associated with metastases outside the prostatic fossa. In conclusion, in patients with BCP, PSMA-PET/CT imaging is warranted to guide (salvage) treatment strategies.
KW - PSMA-PET/CT imaging
KW - biochemical persistence
KW - prostate cancer
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85102312839&origin=inward
UR - http://www.scopus.com/inward/record.url?scp=85102312839&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s13629-021-00320-3
DO - https://doi.org/10.1007/s13629-021-00320-3
M3 - Article
SN - 2211-3037
VL - 11
SP - 54
EP - 61
JO - Tijdschrift voor Urologie
JF - Tijdschrift voor Urologie
IS - 4
ER -